

---

*Erratum*

---

**Erratum to: Generic Development of Topical Dermatologic Products:  
Formulation Development, Process Development, and Testing of Topical  
Dermatologic Products**

**Rong-Kun Chang,<sup>1</sup> Andre Raw,<sup>1,2</sup> Robert Lionberger,<sup>1</sup> and Lawrence Yu<sup>1</sup>**

*Published online 3 September 2015*

**Erratum to: AAPS J  
DOI 10.1208/s12248-012-9411-0**

The authors inadvertently switched the words “qualitative” and “quantitative” in paragraph two under the header “Formulation Design of Generic Topical Drug Products.” The correct sentence reads as follows:

If feasible, the major formulation goal for a generic topical drug product is qualitative sameness (Q1, same components as the RLD) and quantitative sameness (Q2, same components in same concentration as the RLD, i.e., within  $\pm 5\%$ ) to the RLD [5, 6].

---

The online version of the original article can be found at <http://dx.doi.org/10.1208/s12248-012-9411-0>.

<sup>1</sup> Office of Generic Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, 7500 Standish Place, Rockville, MD 20855, USA.

<sup>2</sup> To whom correspondence should be addressed. (e-mail: [andre.raw@fda.hhs.gov](mailto:andre.raw@fda.hhs.gov))